RT Journal Article
SR Electronic
T1 Lying in wait: the resurgence of dengue virus after the Zika epidemic in Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.10.20172247
DO 10.1101/2020.08.10.20172247
A1 Brito, Anderson Fernandes
A1 Machado, Lais Ceschini
A1 Siconelli, Márcio Junio Lima
A1 Oidtman, Rachel J.
A1 Fauver, Joseph R.
A1 de Oliveira Carvalho, Rodrigo Dias
A1 Dezordi, Filipe Zimmer
A1 Pereira, Mylena Ribeiro
A1 de Castro-Jorge, Luiza Antunes
A1 Minto, Elaine Cristina Manini
A1 Passos, Luzia Márcia Romanholi
A1 Kalinich, Chaney C.
A1 Petrone, Mary E.
A1 Allen, Emma
A1 España, Guido Camargo
A1 Huang, Angkana T.
A1 Cummings, Derek A. T.
A1 Baele, Guy
A1 Franca, Rafael Freitas Oliveira
A1 Perkins, T. Alex
A1 da Fonseca, Benedito Antônio Lopes
A1 Wallau, Gabriel Luz
A1 Grubaugh, Nathan D.
YR 2020
UL http://medrxiv.org/content/early/2020/08/11/2020.08.10.20172247.abstract
AB After Zika virus (ZIKV) emerged and caused an epidemic in the Americas in 2016, both Zika and dengue incidence declined in the following years (2017-2018) to a record low in many countries. Following this period of low incidence, dengue resurged in 2019 in Brazil, causing ~2.1 million cases. The reasons for the recent fluctuations in dengue incidence and the maintenance of dengue virus (DENV) through periods of low transmission are unknown. To investigate this, we used a combination of epidemiological and climatological data to estimate dengue force of infection (FOI) and model mosquito-borne transmission suitability since the early 2000s in Brazil. Our estimates of FOI revealed that the rate of DENV transmission in 2018-2019 was exceptionally low, due to a low proportion of susceptible population rather than changes to ecological conditions. This supports the hypothesis that the synchronous decline of dengue in Brazil may be explained by protective immunity from pre-exposure to ZIKV and/or DENV in prior years. Furthermore, we sequenced 69 genomes of dengue virus serotype 1 (DENV-1) and DENV-2 circulating in Northeast and Southeast Brazil, and performed phylogeographic analyses to uncover patterns of viral spread. We found that the outbreaks in Brazil in 2019 were caused by DENV lineages that were circulating locally prior to the Zika epidemic and spread cryptically during the period of low transmission. Despite the period of low transmission, endemic DENV lineages persisted for 5-10 years in Brazil before causing major outbreaks. Our study challenges the paradigm that dengue outbreaks are caused by recently introduced new lineages, but rather they may be driven by established lineages circulating at low levels until the conditions are conducive for outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Hetch Award provided by the Yale Institute for Global Health (NDG), the Interne Fondsen KU Leuven / Internal Funds KU Leuven under grant agreement C14/18/094 (GB), and the Research Foundation, Flanders (Fonds voor Wetenschappelijk Onderzoek, Vlaanderen, G0E1420N; GB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human sampling from Paraiba and Alagoa states used in this study was approved for the Research Ethic Committee (REC) from the Aggeu Magalhaes Institute (IAM) under the CAAE number 10117119.6.0000.5190. Human sampling from Sao Paulo state used in this study was approved by REC from Hospital das Clinicas de Ribeirao Preto (HCRP) process number 12603/2006 and also by DAEP/CSE-FMRP-USP project number 19/2007. Dengue virus sequencing and analysis of a de-identified and limited dataset at the Yale School of Public Health was determined to be exempt from human research determined by a limited Yale Institutional Review Board (IRB) review (IRB protocol ID: 2000025320).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe genomes generated in this study are available on NCBI (accession numbers: will be provided in the final submission; genomic data can be found in our github repository), and datasets used in our analysis can be found at https://github.com/grubaughlab/DENV-genomics/tree/master/paper1. https://github.com/grubaughlab/DENV-genomics/tree/master/paper1